Post Menopausal Osteoporosis - Pipeline Review, H2 2016

Date: October 26, 2016
Pages: 85
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PCC1BAD49D2EN
Leaflet:

Download PDF Leaflet

Post Menopausal Osteoporosis - Pipeline Review, H2 2016
Post Menopausal Osteoporosis - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post Menopausal Osteoporosis - Pipeline Review, H2 2016, provides an overview of the Post Menopausal Osteoporosis (Metabolic Disorders) pipeline landscape.

Postmenopausal osteoporosis is the most common form of osteoporosis. It affects many women after menopause. Symptoms include back pain, loss of height, or spinal deformities such as stooped posture. Risk factors include age, gender, family history, bone structure and body weight. Treatment includes hormone replacement therapy (HRT) and vitamin D analogues.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post Menopausal Osteoporosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Post Menopausal Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post Menopausal Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Post Menopausal Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 5, 1, 1 and 6 respectively for Post Menopausal Osteoporosis.

Post Menopausal Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Post Menopausal Osteoporosis (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Post Menopausal Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Post Menopausal Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Post Menopausal Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Post Menopausal Osteoporosis (Metabolic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Post Menopausal Osteoporosis (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Post Menopausal Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Post Menopausal Osteoporosis Overview
Therapeutics Development
Pipeline Products for Post Menopausal Osteoporosis - Overview
Post Menopausal Osteoporosis - Therapeutics under Development by Companies
Post Menopausal Osteoporosis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Post Menopausal Osteoporosis - Products under Development by Companies
Post Menopausal Osteoporosis - Companies Involved in Therapeutics Development
Amgen Inc.
BiologicsMD, Inc.
Eli Lilly and Company
Enteris BioPharma, Inc.
Intas Pharmaceuticals Ltd.
Ipsen S.A.
Ligand Pharmaceuticals, Inc.
NIBEC
Oncobiologics, Inc.
Paras Biopharmaceuticals Finland Oy
Post Menopausal Osteoporosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
abaloparatide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
blosozumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMD-1111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
calcitonin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
denosumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
denosumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
denosumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Postmenopausal Osteoporosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lasofoxifene tartrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
romosozumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide for Obesity and Post Menopausal Osteoporosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teriparatide biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teriparatide biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Post Menopausal Osteoporosis - Dormant Projects
Post Menopausal Osteoporosis - Discontinued Products
Post Menopausal Osteoporosis - Product Development Milestones
Featured News & Press Releases
Sep 26, 2016: Amgen And UCB Announce U.S. FDA Acceptance Of Biologics License Application For Romosozumab
Sep 19, 2016: Radius Presents Abaloparatide Transdermal Patch Development Program at American Society for Bone and Mineral Research 2016 Annual Meeting
Sep 18, 2016: Radius Announces Publication of Additional Positive Results from the Phase 3 ACTIVE Trial of Abaloparatide-SC in JBMR
Sep 18, 2016: Results From Phase 3 FRAME Study Of Romosozumab Showed Significant Reductions In Both New Vertebral And Clinical Fractures In Postmenopausal Women With Osteoporosis
Sep 14, 2016: Amgen to present romosozumab at Investor Call
Sep 07, 2016: UCB to present results from Phase 3 FRAME Study at the American Society for Bone and Mineral Research Annual Meeting
Aug 16, 2016: JAMA Publishes Positive Phase 3 Data for Abaloparatide in Postmenopausal Women With Osteoporosis
Jul 21, 2016: Amgen And UCB Submit Biologics License Application For Romosozumab To The FDA
Jul 20, 2016: Radius Health Announces Multiple Presentations at the American Society for Bone and Mineral Research 2016 Annual Meeting September 16-19, 2016
Jun 08, 2016: UCB presents Phase 3 data from the STRUCTURE study of Romosozumab at the Annual European Congress of Rheumatology (EULAR 2016)
May 31, 2016: Radius Announces FDA Acceptance for Filing of New Drug Application for Abaloparatide-SC for the Treatment of Postmenopausal Women with Osteoporosis
May 03, 2016: Sermonix Pharmaceuticals Announces Dr. Anthony H. Wild as Board Chairman and Investor
Apr 15, 2016: Radius Announces Three Oral Presentations for Abaloparatide-SC at World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Disease
Apr 01, 2016: Radius Presents Analysis Results on Fracture Risk Reduction in Phase 3 ACTIVE Trial for Investigational Drug Abaloparatide-SC at the ENDO 2016 Annual Meeting
Apr 01, 2016: Amgen And UCB Present Positive Data At ENDO 2016 Comparing Romosozumab With Teriparatide
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 85

LIST OF TABLES

Number of Products under Development for Post Menopausal Osteoporosis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Post Menopausal Osteoporosis - Pipeline by Amgen Inc., H2 2016
Post Menopausal Osteoporosis - Pipeline by BiologicsMD, Inc., H2 2016
Post Menopausal Osteoporosis - Pipeline by Eli Lilly and Company, H2 2016
Post Menopausal Osteoporosis - Pipeline by Enteris BioPharma, Inc., H2 2016
Post Menopausal Osteoporosis - Pipeline by Intas Pharmaceuticals Ltd., H2 2016
Post Menopausal Osteoporosis - Pipeline by Ipsen S.A., H2 2016
Post Menopausal Osteoporosis - Pipeline by Ligand Pharmaceuticals, Inc., H2 2016
Post Menopausal Osteoporosis - Pipeline by NIBEC, H2 2016
Post Menopausal Osteoporosis - Pipeline by Oncobiologics, Inc., H2 2016
Post Menopausal Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Post Menopausal Osteoporosis - Dormant Projects, H2 2016
Post Menopausal Osteoporosis - Discontinued Products, H2 2016 70

LIST OF FIGURES

Number of Products under Development for Post Menopausal Osteoporosis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Ask Your Question

Post Menopausal Osteoporosis - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: